サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1785950

去勢抵抗性前立腺がんの世界市場

Castrate-Resistant Prostate Cancer

出版日
ページ情報
英文 178 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.66円
去勢抵抗性前立腺がんの世界市場
出版日: 2025年08月07日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 178 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

去勢抵抗性前立腺がんの世界市場は2030年までに196億米ドルに達する見込み

2024年に126億米ドルと推定される去勢抵抗性前立腺がんの世界市場は、分析期間2024-2030年にCAGR 7.7%で成長し、2030年には196億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるホルモン療法は、CAGR 8.7%を記録し、分析期間終了時には102億米ドルに達すると予想されます。化学療法分野の成長率は、分析期間のCAGRで7.3％と推定されます。

米国市場は34億米ドルと推定、中国はCAGR 12.1％で成長予測

米国の去勢抵抗性前立腺がん市場は2024年に34億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに42億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは12.1%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ3.8%と7.4%と予測されています。欧州では、ドイツがCAGR 5.1%で成長すると予測されています。

世界の去勢抵抗性前立腺がん市場- 主要動向と促進要因まとめ

なぜ去勢抵抗性前立腺がん治療の需要が増加しているのか？

去勢抵抗性前立腺がん（CRPC）は、アンドロゲン除去療法（ADT）にもかかわらず進行し続ける進行型の前立腺がんです。前立腺がんは世界で最も多く診断されるがんの一つであり、CRPCの発生率は着実に上昇しているため、先進的な治療法の開発が必要とされています。高齢化人口の増加と前立腺がんの有病率の増加が相まって、生存率を改善し患者のQOLを向上させる革新的な治療法に対する需要が高まっています。さらに、早期発見と診断の進歩は、より多くの患者がより早い段階で診断されることに貢献し、より効果的な治療介入を可能にしています。リキッドバイオプシーや次世代シークエンシング技術の導入は、プレシジョン・メディシンのアプローチを強化し、個人の遺伝子プロファイルに合わせた個別化治療レジメンを可能にしました。その結果、製薬会社や研究機関は、CRPCを標的とした新規治療薬の開発に多額の投資を行っています。

新たな治療法はCRPC治療にどのような革命をもたらしているのか？

次世代アンドロゲン受容体阻害薬（ARI）、標的放射性医薬品、免疫療法などの新規治療薬の出現により、CRPC治療の状況は大きく変化しています。エンザルタミド、酢酸アビラテロン、アパルタミドなどの治療薬は治療パラダイムに革命をもたらし、生存率の改善と病勢進行の遅延をもたらしました。これらの治療法は、去勢抵抗性の症例でも活性を維持するアンドロゲン情報伝達経路を標的とすることで効果を発揮します。さらに、ルテチウム-177 PSMAのような放射性リガンド療法の開発は、前立腺特異的膜抗原（PSMA）を発現する腫瘍細胞を選択的に標的とすることにより、臨床試験で有望な結果を示しています。チェックポイント阻害剤や治療用がんワクチンを含む免疫療法も勢いを増しており、従来の治療法に抵抗性を示すCRPC患者に対する有効性を検討する臨床試験が進行中です。これらの技術革新は、CRPCの治療手段を大幅に拡大し、患者に生存期間の延長と疾患管理の改善という新たな希望をもたらしています。

どのような市場動向がCRPC治療薬の採用を促進しているのか？

CRPC市場には、併用療法へのシフトや個別化医療の重視など、いくつかの重要な動向が影響を与えています。アンドロゲン受容体阻害薬と化学療法や放射性医薬品を統合した併用治療戦略の採用が増加しており、単剤治療と比較して優れた臨床転帰が実証されています。製薬会社は、治療効果を高め、薬剤耐性を克服するために、多剤併用治療レジメンに注目しています。もう一つの大きな動向は、腫瘍学研究における人工知能（AI）とビッグデータ解析の統合です。AIを搭載したツールは、膨大なデータセットの解析、バイオマーカーの同定、CRPC患者の治療経路の最適化に活用されています。この技術的進歩は、早期診断を容易にし、患者の層別化を助け、創薬を促進しています。さらに、遠隔医療や遠隔患者モニタリングソリューションの拡大により、特に遠隔地や十分な医療を受けていない地域の患者にとって、専門医による治療へのアクセスが向上しています。

去勢抵抗性前立腺がん市場の主な成長促進要因は？

去勢抵抗性前立腺がん市場の成長は、前立腺がんの罹患率の上昇、標的治療の進歩、がん治療薬開発への研究投資の増加など、いくつかの要因によってもたらされます。前立腺がんに罹患しやすい高齢化人口の増加は、市場拡大に寄与する重要な要因です。さらに、FDAやEMAなどの規制当局による支援と迅速な医薬品承認が、革新的なCRPC治療の導入を加速しています。コンパニオン診断薬やバイオマーカー主導の治療アプローチの台頭は、治療精度と患者の転帰をさらに向上させています。さらに、製薬企業は戦略的提携や合併を積極的に行い、がん領域のポートフォリオを拡大し、急速に進化するCRPC治療の競合情勢において優位に立とうとしています。前立腺がん治療の限界を押し広げる研究努力が続けられ、新たな治療薬が市場に参入するにつれて、CRPCセグメントは大幅な成長を遂げ、患者の生存率を向上させ、世界中の進行前立腺がんの標準治療を変革する態勢が整っています。

セグメント

治療（ホルモン療法、化学療法、放射線療法、免疫療法）

調査対象企業の例

  • Arvinas, Inc.
  • Astellas Pharma Inc.
  • AstraZeneca plc
  • Bayer AG
  • Bayer Oy
  • BeiGene, Ltd.
  • Bristol Myers Squibb
  • Clovis Oncology
  • Daiichi Sankyo Company, Limited
  • Dendreon Pharmaceuticals LLC
  • ESSA Pharma Inc.
  • GlaxoSmithKline plc
  • Innocrin Pharmaceuticals
  • Ipsen S.A.
  • Johnson & Johnson
  • Kintor Pharmaceutical Limited
  • Myovant Sciences Ltd.
  • Novartis International AG
  • Noxopharm Limited
  • Orion Corporation

AIインテグレーション

Global Industry Analystsは、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家からキュレートされたコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP29844

Global Castrate-Resistant Prostate Cancer Market to Reach US$19.6 Billion by 2030

The global market for Castrate-Resistant Prostate Cancer estimated at US$12.6 Billion in the year 2024, is expected to reach US$19.6 Billion by 2030, growing at a CAGR of 7.7% over the analysis period 2024-2030. Hormonal Therapy, one of the segments analyzed in the report, is expected to record a 8.7% CAGR and reach US$10.2 Billion by the end of the analysis period. Growth in the Chemotherapy segment is estimated at 7.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$3.4 Billion While China is Forecast to Grow at 12.1% CAGR

The Castrate-Resistant Prostate Cancer market in the U.S. is estimated at US$3.4 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$4.2 Billion by the year 2030 trailing a CAGR of 12.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.8% and 7.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.1% CAGR.

Global Castrate-Resistant Prostate Cancer Market - Key Trends & Drivers Summarized

Why Is the Demand for Castrate-Resistant Prostate Cancer Treatment Increasing?

Castrate-resistant prostate cancer (CRPC) is an advanced form of prostate cancer that continues to progress despite androgen deprivation therapy (ADT). With prostate cancer being one of the most diagnosed cancers in men worldwide, the incidence of CRPC is steadily rising, necessitating the development of advanced treatment options. The increasing aging population, coupled with the growing prevalence of prostate cancer, is driving demand for innovative therapies that improve survival rates and enhance the quality of life for patients. Furthermore, advancements in early detection and diagnostics have contributed to more patients being diagnosed at an earlier stage, allowing for more effective treatment interventions. The introduction of liquid biopsies and next-generation sequencing technologies has enhanced precision medicine approaches, enabling personalized treatment regimens tailored to an individual’s genetic profile. As a result, pharmaceutical companies and research institutions are investing heavily in the development of novel therapeutics targeting CRPC.

How Are Emerging Therapies Revolutionizing CRPC Treatment?

The landscape of CRPC treatment has evolved significantly with the emergence of novel therapies, including next-generation androgen receptor inhibitors (ARIs), targeted radiopharmaceuticals, and immunotherapy. Drugs such as enzalutamide, abiraterone acetate, and apalutamide have revolutionized the treatment paradigm, offering improved survival benefits and delaying disease progression. These therapies work by targeting androgen signaling pathways, which remain active even in castration-resistant cases. Additionally, the development of radioligand therapies, such as lutetium-177 PSMA, has shown promising results in clinical trials by selectively targeting prostate-specific membrane antigen (PSMA)-expressing tumor cells. Immunotherapy, including checkpoint inhibitors and therapeutic cancer vaccines, is also gaining momentum, with ongoing trials exploring their efficacy in CRPC patients who exhibit resistance to conventional therapies. These innovations are significantly expanding the treatment arsenal for CRPC, offering patients new hope for extended survival and better disease management.

What Market Trends Are Driving the Adoption of CRPC Treatments?

Several key trends are influencing the CRPC market, including the shift toward combination therapies and the growing emphasis on personalized medicine. The increasing adoption of combination treatment strategies, which integrate androgen receptor inhibitors with chemotherapy or radiopharmaceuticals, has demonstrated superior clinical outcomes compared to monotherapy approaches. Pharmaceutical companies are focusing on multi-modal treatment regimens to enhance therapeutic efficacy and overcome drug resistance. Another significant trend is the integration of artificial intelligence (AI) and big data analytics in oncology research. AI-powered tools are being utilized to analyze vast datasets, identify biomarkers, and optimize treatment pathways for CRPC patients. This technological advancement is facilitating early diagnosis, aiding in patient stratification, and expediting drug discovery. Moreover, the expansion of telemedicine and remote patient monitoring solutions is improving access to specialist care, particularly for patients in remote and underserved regions.

What Are the Key Growth Drivers in the Castrate-Resistant Prostate Cancer Market?

The growth in the Castrate-Resistant Prostate Cancer market is driven by several factors, including the rising incidence of prostate cancer, advancements in targeted therapies, and increasing research investments in oncology drug development. The growing aging population, which is more susceptible to prostate cancer, is a significant factor contributing to market expansion. Additionally, regulatory support and expedited drug approvals by agencies such as the FDA and EMA are accelerating the introduction of innovative CRPC treatments. The rise of companion diagnostics and biomarker-driven treatment approaches is further enhancing therapeutic precision and patient outcomes. Furthermore, pharmaceutical companies are actively engaging in strategic collaborations and mergers to expand their oncology portfolios and gain a competitive edge in the rapidly evolving CRPC treatment landscape. As research efforts continue to push the boundaries of prostate cancer treatment, and as new therapeutics enter the market, the CRPC segment is poised for substantial growth, improving patient survival rates and transforming the standard of care for advanced prostate cancer worldwide.

SCOPE OF STUDY:

The report analyzes the Castrate-Resistant Prostate Cancer market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Therapy (Hormonal Therapy, Chemotherapy, Radiotherapy, Immunotherapy)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 34 Featured) -

  • Arvinas, Inc.
  • Astellas Pharma Inc.
  • AstraZeneca plc
  • Bayer AG
  • Bayer Oy
  • BeiGene, Ltd.
  • Bristol Myers Squibb
  • Clovis Oncology
  • Daiichi Sankyo Company, Limited
  • Dendreon Pharmaceuticals LLC
  • ESSA Pharma Inc.
  • GlaxoSmithKline plc
  • Innocrin Pharmaceuticals
  • Ipsen S.A.
  • Johnson & Johnson
  • Kintor Pharmaceutical Limited
  • Myovant Sciences Ltd.
  • Novartis International AG
  • Noxopharm Limited
  • Orion Corporation

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Castrate-Resistant Prostate Cancer - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Global Incidence of Advanced Prostate Cancer Propels Demand for Castrate-Resistant Therapies
    • Technological Advancements in Biomarker Identification Strengthen Personalized Treatment Strategies
    • Growth in Immunotherapy and Targeted Therapy Approvals Expands Addressable Market Opportunity
    • Regulatory Fast-Track Approvals for Novel Agents Accelerate Market Entry and Patient Access
    • Expansion of Clinical Trials and Combination Therapies Throws Spotlight on Pipeline Innovation
    • Increasing Adoption of Androgen Receptor Pathway Inhibitors Drives Long-Term Treatment Outcomes
    • High Unmet Medical Needs in Late-Stage Patients Strengthen Business Case for Novel Drug Development
    • Rising Healthcare Expenditure in Oncology Sustains Market for Premium Therapeutics
    • Digital Health Integration and Remote Monitoring Enhance Patient Engagement and Compliance
    • Emergence of Liquid Biopsy Technologies Supports Early Detection of Therapy Resistance
    • Growing Focus on Quality of Life Outcomes Spurs Innovation in Low-Toxicity Treatment Regimens
    • Global Aging Population and Increased Screening Rates Sustain Demand for Advanced Therapies
    • Challenges in Drug Resistance and Disease Progression Propel Investment in Next-Generation Molecules
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Castrate-Resistant Prostate Cancer Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Castrate-Resistant Prostate Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Castrate-Resistant Prostate Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Castrate-Resistant Prostate Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Hormonal Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Hormonal Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Hormonal Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Chemotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Radiotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Radiotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Radiotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Immunotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Castrate-Resistant Prostate Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 17: USA Recent Past, Current & Future Analysis for Castrate-Resistant Prostate Cancer by Therapy - Hormonal Therapy, Chemotherapy, Radiotherapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 18: USA Historic Review for Castrate-Resistant Prostate Cancer by Therapy - Hormonal Therapy, Chemotherapy, Radiotherapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: USA 15-Year Perspective for Castrate-Resistant Prostate Cancer by Therapy - Percentage Breakdown of Value Sales for Hormonal Therapy, Chemotherapy, Radiotherapy and Immunotherapy for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 20: Canada Recent Past, Current & Future Analysis for Castrate-Resistant Prostate Cancer by Therapy - Hormonal Therapy, Chemotherapy, Radiotherapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 21: Canada Historic Review for Castrate-Resistant Prostate Cancer by Therapy - Hormonal Therapy, Chemotherapy, Radiotherapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: Canada 15-Year Perspective for Castrate-Resistant Prostate Cancer by Therapy - Percentage Breakdown of Value Sales for Hormonal Therapy, Chemotherapy, Radiotherapy and Immunotherapy for the Years 2015, 2025 & 2030
  • JAPAN
    • Castrate-Resistant Prostate Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 23: Japan Recent Past, Current & Future Analysis for Castrate-Resistant Prostate Cancer by Therapy - Hormonal Therapy, Chemotherapy, Radiotherapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 24: Japan Historic Review for Castrate-Resistant Prostate Cancer by Therapy - Hormonal Therapy, Chemotherapy, Radiotherapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: Japan 15-Year Perspective for Castrate-Resistant Prostate Cancer by Therapy - Percentage Breakdown of Value Sales for Hormonal Therapy, Chemotherapy, Radiotherapy and Immunotherapy for the Years 2015, 2025 & 2030
  • CHINA
    • Castrate-Resistant Prostate Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 26: China Recent Past, Current & Future Analysis for Castrate-Resistant Prostate Cancer by Therapy - Hormonal Therapy, Chemotherapy, Radiotherapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: China Historic Review for Castrate-Resistant Prostate Cancer by Therapy - Hormonal Therapy, Chemotherapy, Radiotherapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: China 15-Year Perspective for Castrate-Resistant Prostate Cancer by Therapy - Percentage Breakdown of Value Sales for Hormonal Therapy, Chemotherapy, Radiotherapy and Immunotherapy for the Years 2015, 2025 & 2030
  • EUROPE
    • Castrate-Resistant Prostate Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 29: Europe Recent Past, Current & Future Analysis for Castrate-Resistant Prostate Cancer by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 30: Europe Historic Review for Castrate-Resistant Prostate Cancer by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: Europe 15-Year Perspective for Castrate-Resistant Prostate Cancer by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 32: Europe Recent Past, Current & Future Analysis for Castrate-Resistant Prostate Cancer by Therapy - Hormonal Therapy, Chemotherapy, Radiotherapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Europe Historic Review for Castrate-Resistant Prostate Cancer by Therapy - Hormonal Therapy, Chemotherapy, Radiotherapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: Europe 15-Year Perspective for Castrate-Resistant Prostate Cancer by Therapy - Percentage Breakdown of Value Sales for Hormonal Therapy, Chemotherapy, Radiotherapy and Immunotherapy for the Years 2015, 2025 & 2030
  • FRANCE
    • Castrate-Resistant Prostate Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 35: France Recent Past, Current & Future Analysis for Castrate-Resistant Prostate Cancer by Therapy - Hormonal Therapy, Chemotherapy, Radiotherapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: France Historic Review for Castrate-Resistant Prostate Cancer by Therapy - Hormonal Therapy, Chemotherapy, Radiotherapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: France 15-Year Perspective for Castrate-Resistant Prostate Cancer by Therapy - Percentage Breakdown of Value Sales for Hormonal Therapy, Chemotherapy, Radiotherapy and Immunotherapy for the Years 2015, 2025 & 2030
  • GERMANY
    • Castrate-Resistant Prostate Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 38: Germany Recent Past, Current & Future Analysis for Castrate-Resistant Prostate Cancer by Therapy - Hormonal Therapy, Chemotherapy, Radiotherapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Germany Historic Review for Castrate-Resistant Prostate Cancer by Therapy - Hormonal Therapy, Chemotherapy, Radiotherapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: Germany 15-Year Perspective for Castrate-Resistant Prostate Cancer by Therapy - Percentage Breakdown of Value Sales for Hormonal Therapy, Chemotherapy, Radiotherapy and Immunotherapy for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 41: Italy Recent Past, Current & Future Analysis for Castrate-Resistant Prostate Cancer by Therapy - Hormonal Therapy, Chemotherapy, Radiotherapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Italy Historic Review for Castrate-Resistant Prostate Cancer by Therapy - Hormonal Therapy, Chemotherapy, Radiotherapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: Italy 15-Year Perspective for Castrate-Resistant Prostate Cancer by Therapy - Percentage Breakdown of Value Sales for Hormonal Therapy, Chemotherapy, Radiotherapy and Immunotherapy for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Castrate-Resistant Prostate Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 44: UK Recent Past, Current & Future Analysis for Castrate-Resistant Prostate Cancer by Therapy - Hormonal Therapy, Chemotherapy, Radiotherapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: UK Historic Review for Castrate-Resistant Prostate Cancer by Therapy - Hormonal Therapy, Chemotherapy, Radiotherapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: UK 15-Year Perspective for Castrate-Resistant Prostate Cancer by Therapy - Percentage Breakdown of Value Sales for Hormonal Therapy, Chemotherapy, Radiotherapy and Immunotherapy for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 47: Spain Recent Past, Current & Future Analysis for Castrate-Resistant Prostate Cancer by Therapy - Hormonal Therapy, Chemotherapy, Radiotherapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Spain Historic Review for Castrate-Resistant Prostate Cancer by Therapy - Hormonal Therapy, Chemotherapy, Radiotherapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: Spain 15-Year Perspective for Castrate-Resistant Prostate Cancer by Therapy - Percentage Breakdown of Value Sales for Hormonal Therapy, Chemotherapy, Radiotherapy and Immunotherapy for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 50: Russia Recent Past, Current & Future Analysis for Castrate-Resistant Prostate Cancer by Therapy - Hormonal Therapy, Chemotherapy, Radiotherapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Russia Historic Review for Castrate-Resistant Prostate Cancer by Therapy - Hormonal Therapy, Chemotherapy, Radiotherapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: Russia 15-Year Perspective for Castrate-Resistant Prostate Cancer by Therapy - Percentage Breakdown of Value Sales for Hormonal Therapy, Chemotherapy, Radiotherapy and Immunotherapy for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 53: Rest of Europe Recent Past, Current & Future Analysis for Castrate-Resistant Prostate Cancer by Therapy - Hormonal Therapy, Chemotherapy, Radiotherapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Rest of Europe Historic Review for Castrate-Resistant Prostate Cancer by Therapy - Hormonal Therapy, Chemotherapy, Radiotherapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: Rest of Europe 15-Year Perspective for Castrate-Resistant Prostate Cancer by Therapy - Percentage Breakdown of Value Sales for Hormonal Therapy, Chemotherapy, Radiotherapy and Immunotherapy for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Castrate-Resistant Prostate Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 56: Asia-Pacific Recent Past, Current & Future Analysis for Castrate-Resistant Prostate Cancer by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 57: Asia-Pacific Historic Review for Castrate-Resistant Prostate Cancer by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: Asia-Pacific 15-Year Perspective for Castrate-Resistant Prostate Cancer by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 59: Asia-Pacific Recent Past, Current & Future Analysis for Castrate-Resistant Prostate Cancer by Therapy - Hormonal Therapy, Chemotherapy, Radiotherapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Asia-Pacific Historic Review for Castrate-Resistant Prostate Cancer by Therapy - Hormonal Therapy, Chemotherapy, Radiotherapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: Asia-Pacific 15-Year Perspective for Castrate-Resistant Prostate Cancer by Therapy - Percentage Breakdown of Value Sales for Hormonal Therapy, Chemotherapy, Radiotherapy and Immunotherapy for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Castrate-Resistant Prostate Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 62: Australia Recent Past, Current & Future Analysis for Castrate-Resistant Prostate Cancer by Therapy - Hormonal Therapy, Chemotherapy, Radiotherapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Australia Historic Review for Castrate-Resistant Prostate Cancer by Therapy - Hormonal Therapy, Chemotherapy, Radiotherapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: Australia 15-Year Perspective for Castrate-Resistant Prostate Cancer by Therapy - Percentage Breakdown of Value Sales for Hormonal Therapy, Chemotherapy, Radiotherapy and Immunotherapy for the Years 2015, 2025 & 2030
  • INDIA
    • Castrate-Resistant Prostate Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 65: India Recent Past, Current & Future Analysis for Castrate-Resistant Prostate Cancer by Therapy - Hormonal Therapy, Chemotherapy, Radiotherapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: India Historic Review for Castrate-Resistant Prostate Cancer by Therapy - Hormonal Therapy, Chemotherapy, Radiotherapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: India 15-Year Perspective for Castrate-Resistant Prostate Cancer by Therapy - Percentage Breakdown of Value Sales for Hormonal Therapy, Chemotherapy, Radiotherapy and Immunotherapy for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 68: South Korea Recent Past, Current & Future Analysis for Castrate-Resistant Prostate Cancer by Therapy - Hormonal Therapy, Chemotherapy, Radiotherapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: South Korea Historic Review for Castrate-Resistant Prostate Cancer by Therapy - Hormonal Therapy, Chemotherapy, Radiotherapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: South Korea 15-Year Perspective for Castrate-Resistant Prostate Cancer by Therapy - Percentage Breakdown of Value Sales for Hormonal Therapy, Chemotherapy, Radiotherapy and Immunotherapy for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 71: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Castrate-Resistant Prostate Cancer by Therapy - Hormonal Therapy, Chemotherapy, Radiotherapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Rest of Asia-Pacific Historic Review for Castrate-Resistant Prostate Cancer by Therapy - Hormonal Therapy, Chemotherapy, Radiotherapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: Rest of Asia-Pacific 15-Year Perspective for Castrate-Resistant Prostate Cancer by Therapy - Percentage Breakdown of Value Sales for Hormonal Therapy, Chemotherapy, Radiotherapy and Immunotherapy for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Castrate-Resistant Prostate Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 74: Latin America Recent Past, Current & Future Analysis for Castrate-Resistant Prostate Cancer by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 75: Latin America Historic Review for Castrate-Resistant Prostate Cancer by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: Latin America 15-Year Perspective for Castrate-Resistant Prostate Cancer by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 77: Latin America Recent Past, Current & Future Analysis for Castrate-Resistant Prostate Cancer by Therapy - Hormonal Therapy, Chemotherapy, Radiotherapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Latin America Historic Review for Castrate-Resistant Prostate Cancer by Therapy - Hormonal Therapy, Chemotherapy, Radiotherapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: Latin America 15-Year Perspective for Castrate-Resistant Prostate Cancer by Therapy - Percentage Breakdown of Value Sales for Hormonal Therapy, Chemotherapy, Radiotherapy and Immunotherapy for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 80: Argentina Recent Past, Current & Future Analysis for Castrate-Resistant Prostate Cancer by Therapy - Hormonal Therapy, Chemotherapy, Radiotherapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Argentina Historic Review for Castrate-Resistant Prostate Cancer by Therapy - Hormonal Therapy, Chemotherapy, Radiotherapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: Argentina 15-Year Perspective for Castrate-Resistant Prostate Cancer by Therapy - Percentage Breakdown of Value Sales for Hormonal Therapy, Chemotherapy, Radiotherapy and Immunotherapy for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 83: Brazil Recent Past, Current & Future Analysis for Castrate-Resistant Prostate Cancer by Therapy - Hormonal Therapy, Chemotherapy, Radiotherapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Brazil Historic Review for Castrate-Resistant Prostate Cancer by Therapy - Hormonal Therapy, Chemotherapy, Radiotherapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: Brazil 15-Year Perspective for Castrate-Resistant Prostate Cancer by Therapy - Percentage Breakdown of Value Sales for Hormonal Therapy, Chemotherapy, Radiotherapy and Immunotherapy for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 86: Mexico Recent Past, Current & Future Analysis for Castrate-Resistant Prostate Cancer by Therapy - Hormonal Therapy, Chemotherapy, Radiotherapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Mexico Historic Review for Castrate-Resistant Prostate Cancer by Therapy - Hormonal Therapy, Chemotherapy, Radiotherapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: Mexico 15-Year Perspective for Castrate-Resistant Prostate Cancer by Therapy - Percentage Breakdown of Value Sales for Hormonal Therapy, Chemotherapy, Radiotherapy and Immunotherapy for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 89: Rest of Latin America Recent Past, Current & Future Analysis for Castrate-Resistant Prostate Cancer by Therapy - Hormonal Therapy, Chemotherapy, Radiotherapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Rest of Latin America Historic Review for Castrate-Resistant Prostate Cancer by Therapy - Hormonal Therapy, Chemotherapy, Radiotherapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: Rest of Latin America 15-Year Perspective for Castrate-Resistant Prostate Cancer by Therapy - Percentage Breakdown of Value Sales for Hormonal Therapy, Chemotherapy, Radiotherapy and Immunotherapy for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Castrate-Resistant Prostate Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 92: Middle East Recent Past, Current & Future Analysis for Castrate-Resistant Prostate Cancer by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 93: Middle East Historic Review for Castrate-Resistant Prostate Cancer by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: Middle East 15-Year Perspective for Castrate-Resistant Prostate Cancer by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 95: Middle East Recent Past, Current & Future Analysis for Castrate-Resistant Prostate Cancer by Therapy - Hormonal Therapy, Chemotherapy, Radiotherapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Middle East Historic Review for Castrate-Resistant Prostate Cancer by Therapy - Hormonal Therapy, Chemotherapy, Radiotherapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Middle East 15-Year Perspective for Castrate-Resistant Prostate Cancer by Therapy - Percentage Breakdown of Value Sales for Hormonal Therapy, Chemotherapy, Radiotherapy and Immunotherapy for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 98: Iran Recent Past, Current & Future Analysis for Castrate-Resistant Prostate Cancer by Therapy - Hormonal Therapy, Chemotherapy, Radiotherapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Iran Historic Review for Castrate-Resistant Prostate Cancer by Therapy - Hormonal Therapy, Chemotherapy, Radiotherapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Iran 15-Year Perspective for Castrate-Resistant Prostate Cancer by Therapy - Percentage Breakdown of Value Sales for Hormonal Therapy, Chemotherapy, Radiotherapy and Immunotherapy for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 101: Israel Recent Past, Current & Future Analysis for Castrate-Resistant Prostate Cancer by Therapy - Hormonal Therapy, Chemotherapy, Radiotherapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Israel Historic Review for Castrate-Resistant Prostate Cancer by Therapy - Hormonal Therapy, Chemotherapy, Radiotherapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: Israel 15-Year Perspective for Castrate-Resistant Prostate Cancer by Therapy - Percentage Breakdown of Value Sales for Hormonal Therapy, Chemotherapy, Radiotherapy and Immunotherapy for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 104: Saudi Arabia Recent Past, Current & Future Analysis for Castrate-Resistant Prostate Cancer by Therapy - Hormonal Therapy, Chemotherapy, Radiotherapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Saudi Arabia Historic Review for Castrate-Resistant Prostate Cancer by Therapy - Hormonal Therapy, Chemotherapy, Radiotherapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: Saudi Arabia 15-Year Perspective for Castrate-Resistant Prostate Cancer by Therapy - Percentage Breakdown of Value Sales for Hormonal Therapy, Chemotherapy, Radiotherapy and Immunotherapy for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 107: UAE Recent Past, Current & Future Analysis for Castrate-Resistant Prostate Cancer by Therapy - Hormonal Therapy, Chemotherapy, Radiotherapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: UAE Historic Review for Castrate-Resistant Prostate Cancer by Therapy - Hormonal Therapy, Chemotherapy, Radiotherapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: UAE 15-Year Perspective for Castrate-Resistant Prostate Cancer by Therapy - Percentage Breakdown of Value Sales for Hormonal Therapy, Chemotherapy, Radiotherapy and Immunotherapy for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 110: Rest of Middle East Recent Past, Current & Future Analysis for Castrate-Resistant Prostate Cancer by Therapy - Hormonal Therapy, Chemotherapy, Radiotherapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Rest of Middle East Historic Review for Castrate-Resistant Prostate Cancer by Therapy - Hormonal Therapy, Chemotherapy, Radiotherapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: Rest of Middle East 15-Year Perspective for Castrate-Resistant Prostate Cancer by Therapy - Percentage Breakdown of Value Sales for Hormonal Therapy, Chemotherapy, Radiotherapy and Immunotherapy for the Years 2015, 2025 & 2030
  • AFRICA
    • Castrate-Resistant Prostate Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 113: Africa Recent Past, Current & Future Analysis for Castrate-Resistant Prostate Cancer by Therapy - Hormonal Therapy, Chemotherapy, Radiotherapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Africa Historic Review for Castrate-Resistant Prostate Cancer by Therapy - Hormonal Therapy, Chemotherapy, Radiotherapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: Africa 15-Year Perspective for Castrate-Resistant Prostate Cancer by Therapy - Percentage Breakdown of Value Sales for Hormonal Therapy, Chemotherapy, Radiotherapy and Immunotherapy for the Years 2015, 2025 & 2030

IV. COMPETITION